Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15878572 | 1.00 | DNM1 (0.51) | DNM1EPHX1KDM4EEPHX2MEN1 | |
| SCHEMBL60002 | 0.98 | DNM1 (0.53) | DNM1EPHX1KDM4EEPHX2MEN1 | |
| Water SCHEMBL29264273 | 0.96 | DNM1 (0.51) | DNM1EPHX1KDM4EEPHX2MEN1 | |
| Iodomethane SCHEMBL4824562 | 0.94 | DNM1 (0.50) | DNM1EPHX1KDM4EEPHX2MEN1 | |
| SCHEMBL13670125 | 0.92 | EPHX1 (0.52) | DNM1EPHX1KDM4EEPHX2MEN1 | |
| Hydrochloric Acid SCHEMBL10730965 | 0.92 | DNM1 (0.53) | DNM1EPHX1KDM4EMEN1ALDH1A1 | |
| SCHEMBL36169 | 0.89 | DNM1 (0.55) | DNM1EPHX1KDM4EMEN1ALDH1A1 | |
| SCHEMBL20972405 | 0.86 | EPHX1 (0.63) | DNM1EPHX1KDM4E | |
| SCHEMBL11149127 | 0.85 | EPHX1 (0.58) | DNM1EPHX1KDM4EPAOXHPGD | |
| SCHEMBL3633166 | 0.85 | DNM1 (0.48) | DNM1EPHX1KDM4EEPHX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753926-B1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | SHANGHAI INST ORGANIC CHEMISTRY CAS (CN) | 2024-10-09 | — | — | EP | claimed |
| CN-107286164-A | Purposes of the compound in sitagliptin is prepared and the method for preparing sitagliptin | 武汉臻智生物科技有限公司 | 2017-10-24 | — | — | CN | claimed |
| CN-101935335-A | Crowe saponins as well as preparation method and application thereof in resisting highly pathogenic H5N1 influenza virus | INST MATERIA MEDICA CAMS | 2011-01-05 | — | — | CN | claimed |
| CN-100443486-C | 7-esterified and 7,20-double esterified camptothecine derivant and method for preparing the same and pharmaceutical combination and uses thereof | INST MATERIA MEDICA CAMS (CN) | 2008-12-17 | — | — | CN | claimed |
| CN-100436454-C | Novel harringtonlne derivative, method for making same and its pharmaceutical composition and use thereof | CHINESE ACAD MED SCIENCE (CN) | 2008-11-26 | — | — | CN | claimed |
| CN-100393724-C | 20-esterifiable camptothecine derivative and method for making same and pharmaceutical combination and uses | CHINESE ACAD MED SCIENCE (CN) | 2008-06-11 | — | — | CN | claimed |
| CN-1482128-A | 7-esterified and 7,20-double esterified camptothecine derivant and method for preparing the same and pharmaceutical combination and uses thereof | 中国医学科学院药物研究所 | 2004-03-17 | — | — | CN | claimed |
| CN-1467210-A | 20-esterifiable camptothecine derivative and method for making same and pharmaceutical combination and uses | 中国医学科学院药物研究所 | 2004-01-14 | — | — | CN | claimed |
| CN-1463975-A | Novel harringtonlne derivative, method for making same and its pharmaceutical composition and use thereof | CHINESE ACAD MED SCIENCE (CN) | 2003-12-31 | — | — | CN | claimed |
| CN-119529020-A | Nitrogen-containing heterocyclic compound, and preparation method and application thereof | 成都地奥制药集团有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20210128486-A1 | NANOPARTICLE STRUCTURE | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2021-05-06 | — | — | US | disclosed |
| CN-109824546-A | BOC- (R) -3- amino -4- (2,4,5- trifluorophenyl) butyric acid is condensed impurity and preparation method thereof | 浙江永太科技股份有限公司 | 2019-05-31 | — | — | CN | disclosed |
| CN-107384887-A | A kind of aminopherase, mutant and its application for preparing sitagliptin | 浙江工业大学 | 2017-11-24 | — | — | CN | disclosed |
| CN-107286164-A | Purposes of the compound in sitagliptin is prepared and the method for preparing sitagliptin | 武汉臻智生物科技有限公司 | 2017-10-24 | — | — | CN | disclosed |
| CN-1463975-A | Novel harringtonlne derivative, method for making same and its pharmaceutical composition and use thereof | CHINESE ACAD MED SCIENCE (CN) | 2003-12-31 | — | — | CN | disclosed |
| US-6469065-B1 | COMPOUND THAT DONATES, TRANSFERS OR RELEASES NITRIC OXIDE, ELEVATES ENDOGENOUS LEVELS OF NITRIC OXIDE | NITROMED, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | GARVEY DAVID S (US) | 2002-10-03 | — | — | US | disclosed |
| EP-1109542-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012075-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
| US-4847248-A | 1,4-Benzodiazepines with 5- and 6-membered heterocyclic rings and their use as cholecystokinins and gastrin antagonists | MERCK & CO., INC. (US) | 1989-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | ADRB1, ADRB3, ADRA1D | DNM1 3086/4885EPHX1 806/4885KDM4E 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.